MRSN | Mersana Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.9507 - 2.1150
52 Week Range	1.2200 - 6.28
Beta	1.03
Implied Volatility	103.77%
IV Rank	50.76%
Day's Volume	587,871
Average Volume	1,024,385
Shares Outstanding	123,533,000
Market Cap	252,007,320
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-06-28

Valuation
Profitability
Growth
Health
P/E Ratio	-3.40
Forward P/E Ratio	-3.80
EPS	-0.60
1YR Price Target	18.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	123
Country	USA
Website	MRSN

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.

MRSN's peers: AGIO, BLUE, COGT, KALV, KPTI, TERN, AMLX, ABOS, INZY, XFOR, DAWN, HOOK, THRX, CGEM, RLAY, RCUS, KURA, PTGX, MRUS, REPL, CERE, PLRX, SNDX, RVMD, VRDN, TCRT, TSVT, YMAB, ZYME

*Chart delayed

Analyzing fundamentals for MRSN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see MRSN Fundamentals page.

Watching at MRSN technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on MRSN Technicals page.